title: [Clinical efficacy of TS-1 in refractory bone recurrence of a postoperative squamous lung cancer patient].
abstract: BACKGROUND
  We need more effective treatments for refractory non-small cell lung cancer.
  
  
  METHODS
  A 61-year-old man had a recurrence in the left ninth rib invading the chestwall 4 years after resection of squamous cell lung cancer. The metastatic lesion grew larger even after 3 different regimens of systemic chemotherapy and local irradiation. Then he started to receive 120 mg of TS-1 daily for 28 days followed by 14 days of rest (1 course). A partial response was achieved after 2 courses of the treatment and continued for 6 weeks. Doses of oxycodone hydrochloride could be reduced to one-sixth of the initial dose according to tumor regression.
  
  
  CONCLUSIONS
  This is the first report to show the effectiveness of TS-1 for a refractory recurrence of lung cancer to the bone.
authors.affiliation: Dept. of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine.
authors.forename: Tadashi
authors.initials: T
authors.lastname: Osaki
authors.forename: Takayuki
authors.initials: T
authors.lastname: Takimoto
authors.forename: Mitsugi
authors.initials: M
authors.lastname: Furukawa
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Inoue
authors.forename: Meinoshin
authors.initials: M
authors.lastname: Okumura
authors.forename: Takashi
authors.initials: T
authors.lastname: Niju
authors.forename: Takashi
authors.initials: T
authors.lastname: Kijima
authors.forename: Toru
authors.initials: T
authors.lastname: Kumagai
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Yoshida
authors.forename: Isao
authors.initials: I
authors.lastname: Tachibana
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kawase
mesh_terms: D000284:Administration, Oral; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D011013:Pneumonectomy; D011184:Postoperative Period; D011788:Quality of Life; D012272:Ribs; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid